Exosens/€EXENS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Exosens
Exosens is a high-tech company specializing in the innovation, development, manufacturing, and sale of advanced electro-optical technologies in amplification, detection, and imaging. Its product portfolio includes traveling wave tubes, advanced cameras, neutron and gamma detectors, instrument detectors, and light intensifier tubes, serving sectors such as defense, life sciences, industrial control, and nuclear energy. Founded over 85 years ago, the company rebranded from Photonis Group to Exosens in September 2023 to reflect its expanded technological scope. Headquartered in Mérignac, France, Exosens operates 12 production and R&D sites across Europe and North America, employing over 1,700 individuals. The company's strategic positioning is bolstered by sustained investments in innovation and a series of acquisitions, including Xenics, Proxivision, Telops, and Elmul since December 2022, enhancing its capabilities in detection and imaging technologies. (,)
- Ticker
- €EXENS
- Sector
- Industrials
- Primary listing
- PAR
- Employees
- 2,000
- Headquarters
- Mérignac, France
- Website
- www.exosens.com
Exosens Metrics
BasicAdvanced
€2.9B
96.27
€0.59
0.85
€0.30
0.53%
Price and volume
Market cap
€2.9B
Beta
0.85
52-week high
€72.10
52-week low
€41.00
Average daily volume
81K
Dividend rate
€0.30
Financial strength
Current ratio
2.353
Quick ratio
1.32
Long term debt to equity
0.586
Total debt to equity
0.598
Dividend payout ratio (TTM)
50.43%
Interest coverage (TTM)
7.41%
Profitability
EBITDA (TTM)
104.887
Gross margin (TTM)
60.13%
Net profit margin (TTM)
6.01%
Operating margin (TTM)
17.40%
Effective tax rate (TTM)
23.06%
Revenue per employee (TTM)
€250,000
Management effectiveness
Return on assets (TTM)
6.19%
Return on equity (TTM)
12.71%
Valuation
Price to earnings (TTM)
96.266
Price to revenue (TTM)
5.725
Price to book
6.42
Price to tangible book (TTM)
143.41
Price to free cash flow (TTM)
49.501
Free cash flow yield (TTM)
2.02%
Free cash flow per share (TTM)
1.148
Dividend yield (TTM)
0.53%
Forward dividend yield
0.53%
Growth
Revenue change (TTM)
20.60%
Earnings per share change (TTM)
-45.63%
What the Analysts think about Exosens
Analyst ratings (Buy, Hold, Sell) for Exosens stock.
Analyst projections of the future price of Exosens stock.
Bulls say / Bears say
Exosens raised its 2026 targets to €558–570 million in revenue and €186–192 million in adjusted EBITDA, citing faster capacity growth and strong demand. This points to improving execution as well as sales momentum. (Financial Times)
A first US Army delivery order covers 1,600 BiNOD night-vision systems, with most deliveries expected in 2027. It moves Exosens’ US expansion from contract award towards production and delivery. (Exosens)
A contract for about 17,000 image-intensifier tubes for the Czech Armed Forces runs through 2032. This gives Exosens long-term revenue visibility and strengthens its position as a supplier to NATO forces. (Exosens)
The shares may leave limited room for disappointment: one September valuation comparison put them at about 53.6 times earnings, well above the European aerospace and defence average, while Deutsche Bank said the long-term potential was already reflected in its valuation. (Simply Wall St, MarketScreener)
Capacity expansion requires substantial investment: first-half capital expenditure was 9.2% of sales, and the company expects about 9% for 2026, excluding capitalised research and development. That investment could weigh on cash generation if expanded capacity takes time to convert into sales. (Exosens)
Detection and Imaging faced weaker gross-margin quality in the first quarter: its margin rate fell 261 basis points, reflecting an unfavourable product mix and acquired businesses that had not yet gained scale. If that pressure persists, growth in the segment may deliver less profit than expected. (Exosens)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Exosens Financial Performance
Revenues and expenses
Exosens Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Exosens
AllUSDEURGBP
Fund name | Fund size | €EXENS weighting |
|---|---|---|
Vaneck Defense£DFNG | $7.2B | 0.64% |
VanEck Defense€DFEN | $7.2B | 0.64% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.13% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.13% |
iShares Global Aerospace & Defence€DFND | $1.9B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.